Intrexon | XON - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Agenus USD 38.52M 3.2M 2026-03
Alaunos Therapeutics USD 2.38M 172K 2026-03
Amgen USD 541M 1000K 2026-06
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 141.14M 564K 2026-06
AstraZeneca USD 1.55B 44K 2026-06
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Gilead Sciences USD 1.24B 1000K 2026-06
GlaxoSmithKline GBP 4.08B 20.6M 2026-06
Heron Therapeutics USD 188.31M 4.99M 2025-12
Incyte USD 200.98M 1.03M 2026-06
Intrexon USD 0 0 2024-06
Karyopharm Therapeutics USD 22.54M 4.23M 2026-03
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
MacroGenics USD 63.56M 241K 2026-03
MannKind USD 309.91M 1M 2026-06
Merck USD 2.47B 4.93M 2026-03
Novartis USD 1.9B 7.38M 2026-06
Rigel Pharmaceuticals USD 17K 158K 2024-06
Roche Holding CHF 796.77M 1.15M 2026-06
Thermo Fisher Scientific USD 371.62M 1000 2026-06
Veracyte USD 79.79M 1000 2026-06
Xencor USD 74.33M 265K 2026-06